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1 90 100 N/A 100 N/A 100 N/A
2 87 74 N/A 0 N/A N/A N/A
3 100 100 100 100 100 100 100
4 78 91 10 87 N/A 86 52
5 65 45 0 10 14 N/A N/A
6 100 >95 100 87 100 89 >95
7 >95 94 100 100 100 N/A N/A
8 10 0 0 N/A N/A N/A N/A
9 0 N/A N/A N/A N/A N/A N/A
10 100 41 0 N/A N/A N/A N/A
11 N/A N/A N/A N/A N/A N/A N/A
Number describes percentage of donor DNA.362
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To evaluate the toxicity and efficacy of a RIC regimen including
Treosulfan, followed by allo-HSCT from a 10/10HLA identical un-
related donor, we conducted a prospective study in adult patients
presenting a hematological malignancy in need of allo-HSCT.
The conditioning included: Treosulfan 12g/m2/day iv (day-6 to
day-4), fludarabine 30mg/m2/day iv (day-6 to day -2) and ATG 2.5
mg/kg/day (day-2 to day-1). Peripheral stem cells were used as
HSC source. We included 56 patients, 30 (54%) males and 26 fe-
males with a median age of 57 years (18-65.5). There were 29
AML (14 in CR1, 14 CR2 & 1 \ CR), 8 MDS (1CR1 and 7\
CR) and 1 CML in CR1], 9 MM in PR, 6 CLL (2CR1 & 4PR)
and 3 ALL (1CR1 & 2CR2)]. Among 45 explored for cytogenetics,
23 (51%) were normal and 22 with poor prognostic. Before trans-
plantation, two patients did not receive any previous treatment, 21
received 1 line, 22 two lines and 11 . 2 lines, 49% of patients
were sex-mismatched. For CMV, 43% were -/-, 25% +/+, 28%
+/2 and 1% -/+. For ABO matching, 24% had major incomp. &
24% minor incopm. The median interval diagnosis-allograft was
15 months (4-168). Fifty-four (96%) patients engrafted with a me-
dian time to neutrophils and platelets recovery of 16 days (4-86),
11 (4-82) respectively, 17 patients developed aGVHD grade $ II
with a cumulative incidence at 3 months of 31% (25-38). The cumu-
lative incidence of cGVHD was, at 12 months: 32% (25-39) limited
and 6% (2-10) extensive; at 18 months: 34% (27-47) limited and 8%
(5-12) extensive. After a median follow-up of 13 months (1-57), the
median OS was not reached with a 3 years probability of 52% (38-
71). The median time of EFS was 15 months (8 - 57) with a 3-years
probability of 47% (35-64). The cumulative incidence of relapse at 3
years was 25% (19-31) and the cumulative incidence of TRM at 12,
18 and 36months was 20% (16-27), 23% (16-29) respectively. At the
last follow-up, 22 patients died, 7 due to relapse and 15 due to TRM.
Patients with active cGVHD seem to benefit for the GVL effect on
OS with a high significant difference (HR5 0.2 (0.1-0.6) p5 0.002).
Themultivariate analysis showed: a negative significant impact of both
minor ABO incompatibility (p\ 0.001) and CMV+/2 (p 5 0.01) on
OS, a negative significant impact of patients\CR (p 5 0.03) on re-
lapse. Treosulfan appears to be a good choice for conditioning with
very promising results in terms of OS, relapse and TRM with an
impressive GVL effect.363
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Introduction: Sickle cell disease (SCD) and other severe hemoglo-
binopathies can be cured with allogeneic BMT. However, the large
majority of patients will have no unaffected HLA-matched siblings
or matched unrelated donors. Over the last decade, we have devel-
oped safe and effective haplo-BMT, facilitated by the discovery
that high-dose post-BMTCy can effectively modulate alloreactivity.
Based on this experience, we studied haplo-BMT in patients with
SCD and other hemoglobinopathies.
Patients and Methods: Ten patients with severe SCD and one with
b-thalassemia (pt 8)were enrolled; 10wereAfrican-American,1 Indian,
7 female, and 4 male. The median age was 25 (16-33). Severe disease
was defined as transfusion–dependence, a history of stroke, more
than 2 hospital admissions per year to the hospital due to pain crisis,
acute chest syndrome, etc. Patients received ATG 0.5mg/kg day -9
and 2mg/kg days -8,-7, fludarabine 30mg/m2 days -6 to -2, Cy
14.5mg/kg on -6 and -5, TBI 20Gy on day -1. Unmanipulatedmarrow
was given on day 0. GvHD prophylaxis consisted of Cy 50mg/kg on
days 3 and 4, and tacrolimus to maintain a level of 5-15ng/dl (for one
year) and MMF 1g TID (until day 35) were started on day 5. Patient
4 was found to have anHLA-matched sibling who served as the donor.
Results: Pts 1 and 2 were transplanted before ATGwas instituted, but
otherwise received the same protocol. The median CD3/kg recipient
dose administered was 3.55x10^7 and nucleated cells/kg recipient ad-
ministered was 3.8x10^8. No cases of acute/chronic GvHD have been
diagnosed. Three cases of PRES were seen, and 1 patient demonstrated
CMV reactivation (pt 10) but not CMV disease. Although primarily an
outpatient protocol, all patients required hospital admissions for pain
control or fever. An absolute neutrophil count. 500/mL was achieved
at a median of 17 (0-45) days and unsupported platelets . 50K/mL at
a median of 23 (0-74) days. Three patients rejected the graft (1 primary
and 2 secondary), fully reconstituting with host hematopoiesis. Myeloid
and CD3 engraftment in peripheral blood are shown in the Table.
At a median follow up is 406 (27-1365) days, all patients are alive and 6
are off immunosupression.Conclusions: Non-myeloablative haplo-BMT with post-BMT Cy is
safe and effective in patients with hemoglobinopathies. Although no
GVHD was seen, graft failure and PRES occurred in 3 patients each.
Except for pain, no other complications of sickle cell disease were seen.
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MINOR ABOMISMATCH IS ASSOCIATEDWITH INCREASED NON-RELAPSE
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